Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunogen Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
From ImmunoGen, Inc.
Via Business Wire
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Looking Into Immunogen's Return On Capital Employed
Via Benzinga
After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Expert Ratings for Immunogen
Via Benzinga
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though." 
Via Benzinga
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
From ImmunoGen, Inc.
Via Business Wire
Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
Via Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. 
Via Benzinga
HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
Via Benzinga
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Recap: Immunogen Q3 Earnings
Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, November 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen missed estimated earnings... 
Via Benzinga
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Preview: Immunogen's Earnings
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will... 
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Earnings Scheduled For November 4, 2022
Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for... 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
ImmunoGen Announces Departure of Chief Commercial Officer
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
From ImmunoGen, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS